71.51
0.53%
0.38
시간 외 거래:
50.00
-21.51
-30.08%
전일 마감가:
$71.13
열려 있는:
$70.56
하루 거래량:
3.69M
Relative Volume:
1.80
시가총액:
$13.21B
수익:
$2.53B
순이익/손실:
$-240.23M
주가수익비율:
-45.10
EPS:
-1.5857
순현금흐름:
$-20.46M
1주 성능:
+2.69%
1개월 성능:
+4.61%
6개월 성능:
+15.21%
1년 성능:
+6.70%
이그젝트 사이 Stock (EXAS) Company Profile
명칭
Exact Sciences Corp
전화
608-284-5700
주소
5505 ENDEAVOR LANE, MADISON, WI
이그젝트 사이 Stock (EXAS) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-08-28 | 개시 | Wells Fargo | Overweight |
2024-06-27 | 개시 | Scotiabank | Sector Outperform |
2024-06-03 | 재개 | Jefferies | Buy |
2024-01-02 | 업그레이드 | The Benchmark Company | Hold → Buy |
2023-12-14 | 개시 | Guggenheim | Buy |
2023-12-13 | 개시 | Wolfe Research | Outperform |
2023-10-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
2023-09-28 | 개시 | Bernstein | Outperform |
2023-08-02 | 다운그레이드 | The Benchmark Company | Buy → Hold |
2023-05-10 | 업그레이드 | Craig Hallum | Hold → Buy |
2023-05-05 | 개시 | UBS | Neutral |
2023-03-09 | 업그레이드 | Citigroup | Neutral → Buy |
2023-02-10 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
2023-01-18 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
2022-10-19 | 다운그레이드 | Craig Hallum | Buy → Hold |
2022-08-25 | 개시 | Credit Suisse | Outperform |
2022-06-03 | 개시 | Piper Sandler | Neutral |
2021-11-03 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
2021-07-29 | 재확인 | BTIG Research | Buy |
2021-07-29 | 재확인 | Canaccord Genuity | Buy |
2021-07-29 | 재확인 | Oppenheimer | Outperform |
2021-07-29 | 재확인 | Stifel | Buy |
2021-06-15 | 개시 | Raymond James | Strong Buy |
2021-06-03 | 개시 | Goldman | Buy |
2021-05-25 | 개시 | Wells Fargo | Equal Weight |
2021-01-28 | 개시 | Truist | Buy |
2020-10-29 | 다운그레이드 | UBS | Buy → Neutral |
2020-10-28 | 다운그레이드 | Citigroup | Buy → Neutral |
2020-10-08 | 재개 | BTIG Research | Buy |
2020-04-02 | 개시 | Evercore ISI | Outperform |
2020-01-10 | 재개 | BTIG Research | Buy |
2020-01-07 | 개시 | Citigroup | Buy |
2019-12-13 | 개시 | Dougherty & Company | Buy |
2019-11-15 | 개시 | Stifel | Buy |
2019-10-17 | 재확인 | BofA/Merrill | Buy |
2019-10-01 | 재개 | Craig Hallum | Buy |
2019-09-26 | 개시 | Oppenheimer | Outperform |
2019-02-26 | 업그레이드 | Goldman | Neutral → Buy |
2018-10-09 | 개시 | UBS | Buy |
2018-09-05 | 재개 | The Benchmark Company | Hold |
2018-08-13 | 재확인 | Canaccord Genuity | Buy |
2018-04-03 | 업그레이드 | BTIG Research | Neutral → Buy |
2018-01-29 | 개시 | Goldman | Neutral |
2018-01-08 | 재확인 | The Benchmark Company | Buy |
2017-11-13 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
2017-11-01 | 다운그레이드 | BTIG Research | Buy → Neutral |
모두보기
이그젝트 사이 주식(EXAS)의 최신 뉴스
Exact Sciences: Q3 Earnings Snapshot - San Antonio Express-News
After-hours movers: Super Micro Computer, Exact Sciences, Trump Media & Technology - Investing.com
Exact Sciences Stock Plummets After Worse-Than-Expected Q3 Results, FY24 Guidance Below Estimates - Benzinga
Exact Sciences Corp Q3 2024 Earnings: Revenue at $709M, EPS at -$0.21, Misses Estimates - GuruFocus.com
Exact Sciences shares plummet on weak results, lowered guidance By Investing.com - Investing.com UK
Exact Sciences Announces Third-Quarter 2024 Results - StockTitan
New York State Common Retirement Fund Has $20.19 Million Stock Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
3 Large-Cap Stocks to Buy Ahead of Likely Earnings Beat Tuesday - Yahoo Finance
Exact Sciences Corp (EXAS) Stock Price Up 2.99% on Nov 4 - GuruFocus.com
Exact Sciences to Participate in November Investor Conference - Marketscreener.com
Canaccord Genuity sees upside potential for Exact Sciences shares, lifts PT - Investing.com
Exact Sciences (EXAS) Moves to Strong Buy: Rationale Behind the Upgrade - Yahoo Finance
Exact Sciences (EXAS) Set to Announce Quarterly Earnings on Tuesday - MarketBeat
Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement - Business Wire
8,360 Shares in Exact Sciences Co. (NASDAQ:EXAS) Purchased by Sequoia Financial Advisors LLC - MarketBeat
Exact Sciences Co. (NASDAQ:EXAS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Will Screening Sales Drive Exact Sciences' Q3 Earnings? - Yahoo Finance
Exact Sciences Corp (EXAS) Shares Gap Down to $69.69 on Oct 21 - GuruFocus.com
Can This Beaten-Down Cathie Wood Stock Bounce Back? - MSN
Friedenthal Financial Purchases New Stake in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences Cor (EXAS-Q) QuotePress Release - The Globe and Mail
Exact Sciences Corporation (EXAS) Bounced Back in Q3 - Yahoo Finance
EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening - Yahoo Finance
Artemis Investment Management LLP Invests $7.27 Million in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences EVP sells shares worth over $65k - Investing.com India
Exact Sciences EVP sells shares worth over $65k By Investing.com - Investing.com Australia
Exact Sciences Co. (NASDAQ:EXAS) EVP Brian Baranick Sells 929 Shares - MarketBeat
Exact Sciences Corp (EXAS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Exact Sciences Corp (EXAS) Q2 2024 Earnings Call Highlights: Str - GuruFocus.com
Handelsbanken Fonder AB Acquires 9,400 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences Schedules Third Quarter 2024 Earnings Call - BioSpace
Exact Sciences stock advances on Cologuard Plus approval, BTIG bullish By Investing.com - Investing.com Australia
FMR LLC Bolsters Stake in Exact Sciences Corp - GuruFocus.com
Exact Sciences stock advances on Cologuard Plus approval, BTIG bullish - Investing.com India
FDA greenlights Exact Science’s newest home colorectal cancer test - Medical Device Network
Exact Sciences wins FDA approval for Cologuard Plus colorectal cancer test - Yahoo Finance
Exact Sciences Corporation (EXAS): A Buzzing AI Health Stock to Add to Your Portfolio - Insider Monkey
10 Buzzing AI Health Stocks - Insider Monkey
FDA approves Exact Sciences' advanced CRC screening test By Investing.com - Investing.com South Africa
FDA approves Exact Sciences' advanced CRC screening test - Investing.com India
Exact Sciences shares hold as FDA approves new Cologuard test - Investing.com
FDA greenlights Exact Sciences’ Cologuard Plus - BioWorld Online
Exact Sciences shares hold as FDA approves new Cologuard test By Investing.com - Investing.com Canada
FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test - Yahoo Finance
Is EXAS Stock a Smart Addition to Your Portfolio Right Now? - Yahoo Finance
Exact Sciences (EXAS) Announces FDA Approval of Cologuard Plus Test - StreetInsider.com
FDA Approves Exact Sciences’ Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening - The Bakersfield Californian
Curbstone Financial Management Corp Decreases Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
이그젝트 사이 (EXAS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):